PT  - JOURNAL ARTICLE
AU  - Tiwari, Akshay
AU  - Chowdhury, Shreya
AU  - James, Ananthu
AU  - Chatterjee, Budhaditya
AU  - Dixit, Narendra M.
TI  - Adjusting for specificity of symptoms reveals higher prevalence of asymptomatic SARS-CoV-2 infections than previously estimated
AID  - 10.1101/2024.09.11.24313462
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.11.24313462
4099  - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313462.short
4100  - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313462.full
AB  - Accurate estimates of the prevalence of asymptomatic SARS-CoV-2 infections, ψ, have been important for understanding and forecasting the trajectory of the COVID-19 pandemic. Two-part population-based surveys, which test the infection status and also assess symptoms, have been used to estimate ψ. Here, we identified a widely prevalent confounding effect that compromises these estimates and devised a formalism to adjust for it. The symptoms associated with SARS-CoV-2 infection are not all specific to SARS-CoV-2. They can be triggered by a host of other conditions, such as influenza virus infection. By not accounting for the source of the symptoms, the surveys may misclassify individuals experiencing symptoms from other conditions as symptomatic for SARS-CoV-2, thus underestimating ψ. We developed a rigorous formalism to adjust for this confounding effect and derived a facile formula for the adjusted prevalence, ψadj. We applied it to data from 50 published serosurveys, conducted on the general populations from 28 nations. We found that ψadj was significantly higher than the reported prevalence, ψc (P=3×10−8). The median ψadj was ∼60%, whereas the median ψc was ∼40%. In several instances, ψadj exceeded ψc by >100%. These findings suggest that asymptomatic infections have been far more prevalent than previously estimated. Our formalism can be readily deployed to obtain more accurate estimates of ψ from standard population-based surveys, without additional data collection. The findings have implications for understanding COVID-19 epidemiology and devising more effective interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript